Literature DB >> 25395176

Outcomes following resection of intrahepatic cholangiocarcinoma.

Parissa Tabrizian1, Ghalib Jibara, Jaclyn F Hechtman, Bernardo Franssen, Daniel M Labow, Myron E Schwartz, Swan N Thung, Umut Sarpel.   

Abstract

OBJECTIVES: The aim of this analysis was to examine prognostic features and outcomes in patients undergoing resection for intrahepatic cholangiocarcinoma (ICC).
METHODS: A retrospective chart review was performed in all patients who underwent R0 or R1 resection for primary ICC between 1995 and 2011. Clinical data were abstracted and statistical analyses were conducted in the standard fashion.
RESULTS: A total of 82 patients underwent curative hepatectomy for primary ICC; 51 patients in this cohort developed recurrence. The median follow-up of survivors was 27 months (range: 1-116 months). Recurrences were intrahepatic (65%), associated with multiple tumours (54%) and occurred during the first 2 years after hepatectomy (86%). The main factor associated with recurrence after resection was the presence of satellite lesions. Overall 5-year disease-free survival after primary resection was 16%. Factors associated with poor survival were transfusion and perineural invasion. Treatment of recurrence was undertaken in 89% of patients and repeat surgical resection was performed in 15 patients. The 3-year survival rate after recurrence was 25%. Prolonged survival after recurrence was associated with a solitary tumour recurrence.
CONCLUSIONS: Despite curative resection of ICC, recurrence can be expected to occur in 79% of patients at 5 years. Predictors of survival and recurrence after resection vary in the literature. In patients with recurrence, selection of the optimal treatment remains challenging.
© 2014 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2014        PMID: 25395176      PMCID: PMC4368399          DOI: 10.1111/hpb.12359

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  23 in total

1.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

2.  Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival.

Authors:  Giorgio Ercolani; Gaetano Vetrone; Gian Luca Grazi; Osamu Aramaki; Matteo Cescon; Matteo Ravaioli; Carla Serra; Giovanni Brandi; Antonio Daniele Pinna
Journal:  Ann Surg       Date:  2010-07       Impact factor: 12.969

3.  Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection.

Authors:  Jin Hyoung Kim; Hyung Jin Won; Yong Moon Shin; Pyo Nyun Kim; Sung-Gyu Lee; Shin Hwang
Journal:  Eur J Radiol       Date:  2010-10-14       Impact factor: 3.528

4.  Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study.

Authors:  Matthew V Kiefer; Marissa Albert; Madeline McNally; Mary Robertson; Weijing Sun; Douglas Fraker; Kim Olthoff; Kathleen Christians; Sam Pappas; William Rilling; Michael C Soulen
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience.

Authors:  Gianpaolo Carrafiello; Domenico Laganà; Elisa Cotta; Monica Mangini; Federico Fontana; Francesca Bandiera; Carlo Fugazzola
Journal:  Cardiovasc Intervent Radiol       Date:  2010-04-22       Impact factor: 2.740

6.  Survival analysis of intrahepatic cholangiocarcinoma after resection.

Authors:  Seong Yeon Cho; Sang-Jae Park; Seong Hoon Kim; Sung-Sik Han; Young-Kyu Kim; Kwang-Woong Lee; Soon-Ae Lee; Eun Kyung Hong; Woo Jin Lee; Sang Myung Woo
Journal:  Ann Surg Oncol       Date:  2010-02-18       Impact factor: 5.344

7.  Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy.

Authors:  Ryan Whitney; Cliff Tatum; Mike Hahl; Susan Ellis; Charles R Scoggins; Kelly McMasters; Robert C G Martin
Journal:  J Surg Res       Date:  2009-06-12       Impact factor: 2.192

8.  Significance of repeated resection for recurrent intrahepatic cholangiocarcinoma.

Authors:  M Ohtsuka; F Kimura; H Shimizu; H Yoshidome; A Kato; H Yoshitomi; K Furukawa; N Mitsuhashi; D Takeuchi; T Takayashiki; K Suda; M Miyazaki
Journal:  Hepatogastroenterology       Date:  2009 Jan-Feb

9.  Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.

Authors:  Akshat Saxena; Lourens Bester; Terence C Chua; Francis C Chu; David L Morris
Journal:  Ann Surg Oncol       Date:  2009-10-30       Impact factor: 5.344

10.  Treatment of recurrent intrahepatic cholangiocarcinoma.

Authors:  L Sulpice; M Rayar; E Boucher; M Pracht; B Meunier; K Boudjema
Journal:  Br J Surg       Date:  2012-12       Impact factor: 6.939

View more
  17 in total

Review 1.  Surgical options for intrahepatic cholangiocarcinoma.

Authors:  Kui Wang; Han Zhang; Yong Xia; Jian Liu; Feng Shen
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 2.  Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection.

Authors:  Amir A Rahnemai-Azar; Pallavi Pandey; Ihab Kamel; Timothy M Pawlik
Journal:  Hepat Oncol       Date:  2017-01-20

3.  Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.

Authors:  Suguru Yamashita; Eugene Jon Koay; Guillaume Passot; Rachna Shroff; Kanwal P Raghav; Claudius Conrad; Yun Shin Chun; Thomas A Aloia; Randa Tao; Ahmed Kaseb; Milind Javle; Christopher H Crane; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2016-12-16       Impact factor: 6.860

4.  Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations.

Authors:  Sung Hwan Lee; Eve B Simoneau; Tatiana Karpinets; P Andrew Futreal; Jianjun Zhang; Milind Javle; Jianhua Zhang; Jean-Nicolas Vauthey; Ju-Seog Lee; Jeannelyn S Estrella; Yun Shin Chun
Journal:  Carcinogenesis       Date:  2021-04-17       Impact factor: 4.944

5.  Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models.

Authors:  Alexandre Doussot; Mithat Gonen; Jimme K Wiggers; Bas Groot-Koerkamp; Ronald P DeMatteo; David Fuks; Peter J Allen; Olivier Farges; T Peter Kingham; Jean Marc Regimbeau; Michael I D'Angelica; Daniel Azoulay; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2016-06-11       Impact factor: 6.113

6.  Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma.

Authors:  Kai-Qian Zhou; Wei-Feng Liu; Liu-Xiao Yang; Yun-Fan Sun; Jie Hu; Fei-Yu Chen; Cheng Zhou; Xiang-Yu Zhang; Yuan-Fei Peng; Lei Yu; Jian Zhou; Jia Fan; Zheng Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

7.  HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation.

Authors:  Wei Tian; Jiatong Li; Zhuo Wang; Tong Zhang; Ying Han; Yanyan Liu; Wenfeng Chu; Yu Liu; Baofeng Yang
Journal:  Acta Pharm Sin B       Date:  2021-04-02       Impact factor: 11.413

Review 8.  The role of microRNAs in intrahepatic cholangiocarcinoma.

Authors:  Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  J Cell Mol Med       Date:  2016-09-13       Impact factor: 5.310

9.  Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma.

Authors:  Xingyang Zhu; Xiaoling Song; Kun Xie; Xue Zhang; Wei He; Fubao Liu
Journal:  Int J Mol Med       Date:  2017-08-30       Impact factor: 4.101

10.  Actual over 10-year survival after liver resection for patients with intrahepatic cholangiocarcinoma.

Authors:  Anfeng Si; Jun Li; Hongjun Xiang; Shichao Zhang; Shilei Bai; Pinghua Yang; Xiaofeng Zhang; Yong Xia; Kui Wang; Zhenlin Yan; Wan Yee Lau; Lehua Shi; Feng Shen
Journal:  Oncotarget       Date:  2017-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.